Cannabis-based Indivior to hold capital markets day on December 7

88
2
Cannabis-based Indivior to hold capital markets day on December 7

Indivior will hold a capital markets day on December 7th in New York City. The event will be hosted by Mark Crossley, CEO, along with members of the Indivior executive leadership team, and will detail the company's strategic growth plans and roadmap for long-term shareholder value.

Indivior expects SUBLOCADE injection to achieve a Net Revenue Run Rate of $1 billion by the end of 2025, due to its focus on developing the organized health systems channel and pursuing the large opportunity in the U.S. Justice System. Indivior expects to deliver SUBLOCADE peak potential net revenue of $1.5 billion over the long term, based on the expected positive market dynamics for buprenorphine medication-assissisted treatment and continued execution against its organized health systems strategy.

The company expects to achieve a double-digit percentage net revenue compounded annual growth rate over the medium-term, driven primarily by SUBLOCADE in the United States and a growing net revenue contribution from PERSERIS. Indivior believes that there will be a return to net revenue growth in the rest of the world, based on the current business portfolio, due to new products SUBLOCADE and SUBOXONE film. The company assumes the U.S. market share of SUBOXONE Film, which it does not promote, will trend towards historical analogs for generic medicines.

At its extraordinary general meeting in September of this year, in September of this year, Indivior received strong support from its shareholders for an additional share listing in the United States. Indivior has chosen NASDAQ as its U.S. trading venue after carefully evaluating the options. The additional listing is expected to elevate Indivior's profile in the company's largest market and to attract a broader group of biopharma-focused investors and analysts.

The guidance for FY 2022 was published on October 27, 2022 by the group.

Get your daily dose of cannabis news on Benzinga Cannabis.